Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema
Purpose: To evaluate the efficacy of micropulse laser in the early treatment of diabetic macular edema (DME) and its associated burden of anti-vascular endothelial growth factor (VEGF) injections. Methods: This retrospective comparative study compared a group of 19 eyes with DME treated with micropu...
Gespeichert in:
| Veröffentlicht in: | European journal of ophthalmology 2018-01, Vol.28 (1), p.68-73 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 73 |
|---|---|
| container_issue | 1 |
| container_start_page | 68 |
| container_title | European journal of ophthalmology |
| container_volume | 28 |
| creator | Moisseiev, Elad Abbassi, Sam Thinda, Sumeer Yoon, Joseph Yiu, Glenn Morse, Lawrence S. |
| description | Purpose:
To evaluate the efficacy of micropulse laser in the early treatment of diabetic macular edema (DME) and its associated burden of anti-vascular endothelial growth factor (VEGF) injections.
Methods:
This retrospective comparative study compared a group of 19 eyes with DME treated with micropulse laser to a matched control group of 19 eyes with DME treated with ranibizumab injections without micropulse laser. Recorded parameters included previous medical and ocular history, previous and subsequent ranibizumab injections administered for DME, visual acuity (VA), central macular thickness throughout the follow-up period, and the occurrence of any complications.
Results:
The improvement in VA was comparable in both groups, at 12 months and at the final follow-up. Patients treated with micropulse laser required significantly fewer ranibizumab injections than their controls, both at 12 months (1.7 ± 2.3 vs 5.6 ± 2.1) and by the end of the follow-up (2.6 ± 3.3 vs 9.3 ± 5.1) (p |
| doi_str_mv | 10.5301/ejo.5001000 |
| format | Article |
| fullrecord | <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_5301_ejo_5001000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.5301_ejo.5001000</sage_id><sourcerecordid>10.5301_ejo.5001000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c322t-24f89a7af7cba7ebecb7a65fb8d033d00c7d934f4ec6208e245c015a4a9421833</originalsourceid><addsrcrecordid>eNptkE1LxDAQhoMo7rp68i45CtJ1kqZN9yjL7iosePDjWtJkalP6RdIi_nsju3ryNMPw8DLvQ8g1g2USA7vHul8mAAwATsicSS6iFFh6GnbGIUolZzNy4X0NwGEl-DmZ8UzGTKzEnFQvUzFWDn3VN4a2Vrt-mBqPtFEeHXVoJo2eqm600ftmt6W2q1GPtu9oMTmDXTjQQY0Wu9HTTztW1FhV4Gg1bZWeGuUoGmzVJTkrVQi-Os4FedtuXteP0f5597R-2Ec65nyMuCizlZKqlLpQEgvUhVRpUhaZgTg2AFqaVSxKgTrlkCEXiQaWKKFCM5bF8YLcHXJDE-8dlvngbKvcV84g__GVB1_50Vegbw70MBUtmj_2V1AAbg-AVx-Y1_3kuvD9v1nfDVR0eg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Moisseiev, Elad ; Abbassi, Sam ; Thinda, Sumeer ; Yoon, Joseph ; Yiu, Glenn ; Morse, Lawrence S.</creator><creatorcontrib>Moisseiev, Elad ; Abbassi, Sam ; Thinda, Sumeer ; Yoon, Joseph ; Yiu, Glenn ; Morse, Lawrence S.</creatorcontrib><description>Purpose:
To evaluate the efficacy of micropulse laser in the early treatment of diabetic macular edema (DME) and its associated burden of anti-vascular endothelial growth factor (VEGF) injections.
Methods:
This retrospective comparative study compared a group of 19 eyes with DME treated with micropulse laser to a matched control group of 19 eyes with DME treated with ranibizumab injections without micropulse laser. Recorded parameters included previous medical and ocular history, previous and subsequent ranibizumab injections administered for DME, visual acuity (VA), central macular thickness throughout the follow-up period, and the occurrence of any complications.
Results:
The improvement in VA was comparable in both groups, at 12 months and at the final follow-up. Patients treated with micropulse laser required significantly fewer ranibizumab injections than their controls, both at 12 months (1.7 ± 2.3 vs 5.6 ± 2.1) and by the end of the follow-up (2.6 ± 3.3 vs 9.3 ± 5.1) (p<0.001 for both). No complications related to the micropulse laser were encountered.
Conclusions:
Micropulse laser is a safe and effective treatment for DME, which may achieve comparable improvement in VA along with a significant reduction in the burden of anti-VEGF injections. We suggest a treatment approach for its inclusion in the early stages of DME.</description><identifier>ISSN: 1120-6721</identifier><identifier>EISSN: 1724-6016</identifier><identifier>DOI: 10.5301/ejo.5001000</identifier><identifier>PMID: 28731494</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Aged ; Angiogenesis Inhibitors - administration & dosage ; Diabetic Retinopathy - complications ; Diabetic Retinopathy - physiopathology ; Diabetic Retinopathy - therapy ; Female ; Follow-Up Studies ; Humans ; Intravitreal Injections ; Laser Therapy - methods ; Lasers, Semiconductor - therapeutic use ; Macular Edema - diagnosis ; Macular Edema - etiology ; Macular Edema - therapy ; Male ; Middle Aged ; Ranibizumab - administration & dosage ; Retrospective Studies ; Tomography, Optical Coherence - methods ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity</subject><ispartof>European journal of ophthalmology, 2018-01, Vol.28 (1), p.68-73</ispartof><rights>The Author(s) 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c322t-24f89a7af7cba7ebecb7a65fb8d033d00c7d934f4ec6208e245c015a4a9421833</citedby><cites>FETCH-LOGICAL-c322t-24f89a7af7cba7ebecb7a65fb8d033d00c7d934f4ec6208e245c015a4a9421833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.5301/ejo.5001000$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.5301/ejo.5001000$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28731494$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moisseiev, Elad</creatorcontrib><creatorcontrib>Abbassi, Sam</creatorcontrib><creatorcontrib>Thinda, Sumeer</creatorcontrib><creatorcontrib>Yoon, Joseph</creatorcontrib><creatorcontrib>Yiu, Glenn</creatorcontrib><creatorcontrib>Morse, Lawrence S.</creatorcontrib><title>Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema</title><title>European journal of ophthalmology</title><addtitle>Eur J Ophthalmol</addtitle><description>Purpose:
To evaluate the efficacy of micropulse laser in the early treatment of diabetic macular edema (DME) and its associated burden of anti-vascular endothelial growth factor (VEGF) injections.
Methods:
This retrospective comparative study compared a group of 19 eyes with DME treated with micropulse laser to a matched control group of 19 eyes with DME treated with ranibizumab injections without micropulse laser. Recorded parameters included previous medical and ocular history, previous and subsequent ranibizumab injections administered for DME, visual acuity (VA), central macular thickness throughout the follow-up period, and the occurrence of any complications.
Results:
The improvement in VA was comparable in both groups, at 12 months and at the final follow-up. Patients treated with micropulse laser required significantly fewer ranibizumab injections than their controls, both at 12 months (1.7 ± 2.3 vs 5.6 ± 2.1) and by the end of the follow-up (2.6 ± 3.3 vs 9.3 ± 5.1) (p<0.001 for both). No complications related to the micropulse laser were encountered.
Conclusions:
Micropulse laser is a safe and effective treatment for DME, which may achieve comparable improvement in VA along with a significant reduction in the burden of anti-VEGF injections. We suggest a treatment approach for its inclusion in the early stages of DME.</description><subject>Aged</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Diabetic Retinopathy - complications</subject><subject>Diabetic Retinopathy - physiopathology</subject><subject>Diabetic Retinopathy - therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Laser Therapy - methods</subject><subject>Lasers, Semiconductor - therapeutic use</subject><subject>Macular Edema - diagnosis</subject><subject>Macular Edema - etiology</subject><subject>Macular Edema - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ranibizumab - administration & dosage</subject><subject>Retrospective Studies</subject><subject>Tomography, Optical Coherence - methods</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Visual Acuity</subject><issn>1120-6721</issn><issn>1724-6016</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkE1LxDAQhoMo7rp68i45CtJ1kqZN9yjL7iosePDjWtJkalP6RdIi_nsju3ryNMPw8DLvQ8g1g2USA7vHul8mAAwATsicSS6iFFh6GnbGIUolZzNy4X0NwGEl-DmZ8UzGTKzEnFQvUzFWDn3VN4a2Vrt-mBqPtFEeHXVoJo2eqm600ftmt6W2q1GPtu9oMTmDXTjQQY0Wu9HTTztW1FhV4Gg1bZWeGuUoGmzVJTkrVQi-Os4FedtuXteP0f5597R-2Ec65nyMuCizlZKqlLpQEgvUhVRpUhaZgTg2AFqaVSxKgTrlkCEXiQaWKKFCM5bF8YLcHXJDE-8dlvngbKvcV84g__GVB1_50Vegbw70MBUtmj_2V1AAbg-AVx-Y1_3kuvD9v1nfDVR0eg</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Moisseiev, Elad</creator><creator>Abbassi, Sam</creator><creator>Thinda, Sumeer</creator><creator>Yoon, Joseph</creator><creator>Yiu, Glenn</creator><creator>Morse, Lawrence S.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201801</creationdate><title>Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema</title><author>Moisseiev, Elad ; Abbassi, Sam ; Thinda, Sumeer ; Yoon, Joseph ; Yiu, Glenn ; Morse, Lawrence S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c322t-24f89a7af7cba7ebecb7a65fb8d033d00c7d934f4ec6208e245c015a4a9421833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Diabetic Retinopathy - complications</topic><topic>Diabetic Retinopathy - physiopathology</topic><topic>Diabetic Retinopathy - therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Laser Therapy - methods</topic><topic>Lasers, Semiconductor - therapeutic use</topic><topic>Macular Edema - diagnosis</topic><topic>Macular Edema - etiology</topic><topic>Macular Edema - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ranibizumab - administration & dosage</topic><topic>Retrospective Studies</topic><topic>Tomography, Optical Coherence - methods</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moisseiev, Elad</creatorcontrib><creatorcontrib>Abbassi, Sam</creatorcontrib><creatorcontrib>Thinda, Sumeer</creatorcontrib><creatorcontrib>Yoon, Joseph</creatorcontrib><creatorcontrib>Yiu, Glenn</creatorcontrib><creatorcontrib>Morse, Lawrence S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>European journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moisseiev, Elad</au><au>Abbassi, Sam</au><au>Thinda, Sumeer</au><au>Yoon, Joseph</au><au>Yiu, Glenn</au><au>Morse, Lawrence S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema</atitle><jtitle>European journal of ophthalmology</jtitle><addtitle>Eur J Ophthalmol</addtitle><date>2018-01</date><risdate>2018</risdate><volume>28</volume><issue>1</issue><spage>68</spage><epage>73</epage><pages>68-73</pages><issn>1120-6721</issn><eissn>1724-6016</eissn><abstract>Purpose:
To evaluate the efficacy of micropulse laser in the early treatment of diabetic macular edema (DME) and its associated burden of anti-vascular endothelial growth factor (VEGF) injections.
Methods:
This retrospective comparative study compared a group of 19 eyes with DME treated with micropulse laser to a matched control group of 19 eyes with DME treated with ranibizumab injections without micropulse laser. Recorded parameters included previous medical and ocular history, previous and subsequent ranibizumab injections administered for DME, visual acuity (VA), central macular thickness throughout the follow-up period, and the occurrence of any complications.
Results:
The improvement in VA was comparable in both groups, at 12 months and at the final follow-up. Patients treated with micropulse laser required significantly fewer ranibizumab injections than their controls, both at 12 months (1.7 ± 2.3 vs 5.6 ± 2.1) and by the end of the follow-up (2.6 ± 3.3 vs 9.3 ± 5.1) (p<0.001 for both). No complications related to the micropulse laser were encountered.
Conclusions:
Micropulse laser is a safe and effective treatment for DME, which may achieve comparable improvement in VA along with a significant reduction in the burden of anti-VEGF injections. We suggest a treatment approach for its inclusion in the early stages of DME.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>28731494</pmid><doi>10.5301/ejo.5001000</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1120-6721 |
| ispartof | European journal of ophthalmology, 2018-01, Vol.28 (1), p.68-73 |
| issn | 1120-6721 1724-6016 |
| language | eng |
| recordid | cdi_crossref_primary_10_5301_ejo_5001000 |
| source | MEDLINE; SAGE Complete |
| subjects | Aged Angiogenesis Inhibitors - administration & dosage Diabetic Retinopathy - complications Diabetic Retinopathy - physiopathology Diabetic Retinopathy - therapy Female Follow-Up Studies Humans Intravitreal Injections Laser Therapy - methods Lasers, Semiconductor - therapeutic use Macular Edema - diagnosis Macular Edema - etiology Macular Edema - therapy Male Middle Aged Ranibizumab - administration & dosage Retrospective Studies Tomography, Optical Coherence - methods Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity |
| title | Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T15%3A17%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subthreshold%20micropulse%20laser%20reduces%20anti-VEGF%20injection%20burden%20in%20patients%20with%20diabetic%20macular%20edema&rft.jtitle=European%20journal%20of%20ophthalmology&rft.au=Moisseiev,%20Elad&rft.date=2018-01&rft.volume=28&rft.issue=1&rft.spage=68&rft.epage=73&rft.pages=68-73&rft.issn=1120-6721&rft.eissn=1724-6016&rft_id=info:doi/10.5301/ejo.5001000&rft_dat=%3Csage_cross%3E10.5301_ejo.5001000%3C/sage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28731494&rft_sage_id=10.5301_ejo.5001000&rfr_iscdi=true |